All In Biotech

Drug Trial Radar · NCT00125164

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Prepubertal Children With Growth Failure Associated With Primary IGF-1 Deficiency: A Phase 3, Randomized, Open Label, Observation-Controlled, Multicenter, Parallel-Dose Comparison Trial

Last checked: Nov 20, 2026Latest source record: Sep 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 137 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

137

Actual

Start

Mar 2004

Primary completion

Jul 2008

Study completion Jul 2008

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Jul 29, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of prepubertal children with short stature associated with low IGF-1 levels but who produce sufficient growth hormone (GH). Subjects will be randomized to either an observation arm or to active treatment.

Conditions

  • Growth Disorders
  • Insulin-Like Growth Factor-1 Deficiency

Interventions

  • rhIGF-1 (mecasermin, Tercica, Inc.)Drug

    Twice Daily Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Height Velocity During the First Year - Intent to Treat (ITT)PopulationTime frame: Measured at baseline and at one year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ipsen (formerly Tercica)

    Brisbane, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.